Bausch & Lomb Seals Deal Acquires Xiidra and Ophthalmology Portfolio from Novartis for $1.7B
- Jul 6, 2023
- 1 min read
Vaughan, ON, June 30, 2023 (Reuters) -- Bausch & Lomb announced a significant move on Friday, with the acquisition of multiple eye-care products from Novartis for a substantial sum of $1.75 billion. As part of the agreement, Bausch + Lomb will take ownership of several valuable assets, including the anti-inflammatory eye drop Xiidra, libvatrep for chronic ocular surface pain, and the rights to utilize Novartis' AcuStream dry-eye drug delivery device.
Read full article here.
Comments